<rdf:RDF
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:ns1="http://metadb.riken.jp/db/SciNetS_rib124i/"
    xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
    xmlns:ns4="http://creativecommons.org/ns#"
    xmlns:ns3="http://database.riken.jp/sw/item/">
  <ns1:crib124s1i rdf:about="http://metadb.riken.jp/db/SciNetS_rib124i/crib124s1rib124u17064i">
    <ns1:prib124u2i rdf:resource="http://metadb.riken.jp/db/SciNetS_rib124i/crib124u1rib124u5i"/>
    <ns1:prib124u1i xml:lang="en">&lt;p&gt;This group represents a predicted acid sphingomyelinase-like phosphodiesterase (ASMLPD). The ASMLPD 3b precursor has a possible interaction with the anti-CD20 monoclonal antibodies called rituximab [&lt;cite idref="PUB00043440"/&gt;]. This indicates that it may have a role in immune responses. &lt;/p&gt;</ns1:prib124u1i>
    <ns1:prib124s4i rdf:resource="http://metadb.riken.jp/db/SciNetS_rib124i/crib124s1rib124u4843i"/>
    <ns4:attributionURL rdf:resource="http://www.ebi.ac.uk/interpro/ISearch?query=IPR017064"/>
    <rdfs:seeAlso rdf:resource="http://database.riken.jp/sw/item/crib124s1rib124u17064i"/>
    <rdfs:label xml:lang="en">Acid sphingomyelinase-like phosphodiesterase, predicted</rdfs:label>
  </ns1:crib124s1i>
</rdf:RDF>